This award recognises Hikma’s efforts to alleviate the shortages of Thiotepa for Injection and Phentolamine Mesylate for Injection. Hikma acquired both of these products from Bedford Laboratories in 2014. At the time of the acquisition, both products were on shortage. Since then, Hikma was able to tech transfer these products to its FDA compliant manufacturing facilities and expedite the submission of post-approval supplements to the FDA. Both products were relaunched by Hikma in 2015. Hikma markets these products through West-Ward Pharmaceuticals, its wholly owned subsidiary in the US. The FDA established this award programme to recognise companies for making a substantial contribution to preventing or alleviating critical drug shortages, as well as recognising companies’ commitments to public health and quality manufacturing. Said Darwazah, Chairman and CEO of Hikma, said, “We are delighted to have received this award. We have been working closely with the FDA to alleviate drug shortages, ensuring critical care products are reaching patients in need. Our continued investment in quality across our manufacturing plants has positioned us as reliable partner for the FDA, and are very pleased our efforts have been recognised.”